Literature DB >> 3187630

Panretinal photocoagulation in the management of neovascular glaucoma.

L F Cashwell1, W P Marks.   

Abstract

We report a retrospective evaluation of the role of panretinal photocoagulation in the primary treatment of neovascular glaucoma. Thirty-six eyes (32 patients) received aggressive argon laser panretinal photocoagulation beginning as soon as feasible after diagnosis of the developing neovascular glaucoma. Thirty eyes were stabilized by photocoagulation, though 25 required long-term glaucoma medications. Six eyes required additional procedures. Vision deteriorated in 21 of the 36 eyes (nine eyes finally having "no light perception") during the 32.8-month follow-up. Intraocular pressure averaged 39.0 mm Hg before photocoagulation and 21.2 mm Hg at study's end. All 36 eyes were retained and remain comfortable. We conclude that panretinal photocoagulation plays an important role in the management of neovascular glaucoma.

Entities:  

Mesh:

Year:  1988        PMID: 3187630     DOI: 10.1097/00007611-198811000-00008

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  3 in total

1.  Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab.

Authors:  L C Olmos; M S Sayed; A L Moraczewski; S J Gedde; P J Rosenfeld; W Shi; W J Feuer; R K Lee
Journal:  Eye (Lond)       Date:  2015-12-18       Impact factor: 3.775

2.  Surgical results of pars plana vitrectomy combined with pars plana lensectomy with anterior capsule preservation, endophotocoagulation, and silicon oil tamponade for neovascular glaucoma.

Authors:  Nozomi Kinoshita; Ayumi Ota; Fumihiko Toyoda; Hiroko Yamagami; Akihiro Kakehashi
Journal:  Clin Ophthalmol       Date:  2011-12-16

3.  Anterior chamber depth and intraocular pressure following panretinal argon laser photocoagulation for diabetic retinopathy.

Authors:  Hakki Birinci; M Rasih Abidinoglu; Ihsan Oge
Journal:  Ann Saudi Med       Date:  2006 Jan-Feb       Impact factor: 1.526

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.